HKAPI x HKSTP - How AI is Transforming Drug Discovery and Clinical Trial Design
The “Symposium – How AI is Transforming Drug Discovery and Clinical Trial Design” was a huge success, with drug developers and investors in attendance to learn about the latest AI technologies in drug discovery and clinical development. The event, organized by Hong Kong Science & Technology Park and co-organized by HKAPI, showcased the cutting-edge AI technologies from Hong Kong Science Park and provided valuable insights into how AI can predict and optimize the probability of success for clinical trials of investigational drugs.
After Dr Grace Lau, the Head of Institute for Translational Research, Hong Kong Science and Technology Parks Corporate, gave an overview of clinical trial landscape in Hong Kong and the region, Ms Elaine Philips, HKAPI Board Member and the Sponsor of the Partnering for Medical Advancement (PMA) Task Force , opened the symposium by introducing the HKAPI and the collaborative projects of the PMA task force and our partners in promoting AI and big data application
The symposium was well-received by attendees, who appreciated the opportunity to learn about the latest advancements in AI and how it can be applied to drug discovery and clinical development. The onsite networking session also provided a platform for attendees to make new connections and spark new inspirations.
Overall, the “Symposium – How AI is Transforming Drug Discovery and Clinical Trial Design” was a resounding success, providing valuable insights and opportunities for attendees to learn, connect, and grow. We would like to thank HKSTP for their efforts in organizing this valuable event and look forward to future opportunities to learn and grow together.
